ATXS vs ARDX

Analysts rate Ardelyx, Inc.

(ARDX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ardelyx, Inc.

(ARDX) delivered a total return of +313. 0%, compared to +7. 0% for Astria Therapeutics, Inc. (ATXS). Over 10 years, the gap is even starker: ARDX returned +263. 5% versus ATXS's -95. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ardelyx, Inc.

(ARDX) is the lower-risk stock at 0. 87β versus Astria Therapeutics, Inc. 's 1. 32β — meaning ATXS is approximately 53% more volatile than ARDX relative to the S&P 500. On balance sheet safety, Astria Therapeutics, Inc. (ATXS) carries a lower debt/equity ratio of 2% versus 127% for Ardelyx, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Astria Therapeutics, Inc.

grew EPS 30. 6% year-over-year, compared to -52. 9% for Ardelyx, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ardelyx, Inc.

(ARDX) is the more profitable company, earning -15. 1% net margin versus -175. 7% for Astria Therapeutics, Inc. — meaning it keeps -15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARDX leads at -10. 1% versus -193. 4% for ATXS. At the gross margin level — before operating expenses — ATXS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ardelyx, Inc.

(ARDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), +263. 5% 10Y return). Both have compounded well over 10 years (ARDX: +263. 5%, ATXS: -95. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ATXS is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.